Virpax's Liposomal Bupivacaine Candidate Associated With No Neurotoxicity In Animal Studies

Virpax Pharmaceuticals Inc VRPX has announced data from a sciatic nerve preclinical study designed to evaluate Probudur, Virpax's liposomal bupivacaine product candidate.
This study's objective was to assess neurotoxicity resulting from a long residence time of a local anesthetic in proximity to the sciatic nerve in rabbits.
The rabbit limbs dosed with the liposomal prolonged bupivacaine release (Probudur), at ten times more than free bupivacaine, showed no nerve damage signs.
Further, nerves injected with Probudur showed mild signs of inflammation and small residues of the hydrogel in granulomas, indicating a long residence time of the hydrogel at the injection site, but no histopathological signs of nerve damage.
Price Action: VRPX shares are up 5.26% at $5.1 during the market trading session on the last check Monday.